Evidence map›Paper›PMID 34053062›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Gut Microbiota, the Immune System, and Cytotoxic T Lymphocytes.

Carmela Cosola, Maria Teresa Rocchetti, Loreto Gesualdo

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. The Human Gut Microbiota: A Dynamic Biologic Factory.Advances in biochemical engineering/biotechnology · 2025
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Gut Microbial Alterations in Diarrheal Baer's Pochards (Frontiers in veterinary science · 2021
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Carmela CosolaDepartment of Emergency and Organ Transplantation, Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Bari, Italy. carmela.cosola@uniba.it.
Maria Teresa RocchettiMolecular Medicine Center, Clinical Pathology, University of Foggia - Azienda Ospedaliera Universitaria Foggia, Foggia, Italy.
Loreto GesualdoDepartment of Emergency and Organ Transplantation, Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Bari, Italy.
University of Bari Aldo Moro · ITUniversity of Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut microbiota, the largest microbial community living in the human body, exerts a variety of metabolic, structural, and functional actions. In particular, it is essential for the full immune system development and maturation, as demonstrated by studies on germ-free animals, showing immune impairment at different levels. Gut microbiota shapes the immune responses by promoting immune tolerance toward food antigens and commensals in the steady state. This process is orchestrated by a complex network of both microbial and human cells and molecular mediators. Microbiota eubiosis is fundamental in establishing a correct balance between tolerance and immunity. Contrarily, microbiota dysbiosis is correlated with alterations in the immune balance, as evidenced in intestinal pathologies characterized by aberrant immune responses, such as inflammatory bowel disease and celiac disease, in which either break of tolerance against commensals or microbial dysbiosis is reported. On the other hand, a role for gut microbiota in stimulating the cytotoxic immune response in contexts of immunosuppression, like the ones featuring tumors and vaccinations, is emerging. The bifaceted role of gut microbiota in the delicate balance between tolerance and immunity could be exploited in order to develop pioneering therapeutic strategies, complementary to the pharmacological ones, thus representing a field worthy of further studies specifically focused on this topic.

Indexed as

Immune ToleranceCeliac DiseaseDendritic CellsDysbiosisGastrointestinal MicrobiomeHumansImmune Checkpoint InhibitorsImmunoglobulin AImmunotherapyInflammatory Bowel DiseasesNeoplasmsT-Lymphocytes, CytotoxicT-Lymphocytes, RegulatoryImmune Checkpoint InhibitorsImmunoglobulin Aceliac diseaseCytotoxic T lymphocytesDendritic cellsGut-associated lymphoid tissueGut microbiotaImmune checkpoint therapyImmunityInflammatory bowel diseaseToleranceTreg cellsTumors

Identifiers

PMID34053062
OpenAlexW3165801417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.